Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nathwani, D.
Right arrow Articles by Tice, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nathwani, D.
Right arrow Articles by Tice, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 149-154
© 2002 The British Society for Antimicrobial Chemotherapy

Antimicrobial practice

Ambulatory antimicrobial use: the value of an outcomes registry

Dilip Nathwania,* and Alan Ticeb

a Infection and Immunodeficiency Unit, Ninewells Hospital, Tayside University Hospitals, Dundee DD1 9SY, UK; b Infections Limited, PS, Stadium Way Consulting, 401 Broadway, Tacoma, WA 98402, USA

The opportunity for treating many serious infections in the community or ambulatory setting is growing. Outpatient parenteral antimicrobial therapy (OPAT) provides many potential advantages to the patient, hospital and clinician, including quality of life, cost savings and reduced risk of hospital-acquired infections due to antibiotic-resistant organisms. However, despite the evolution of this type of care in many countries, there have been continued questions and concerns about its safety and effectiveness. As with many new forms of therapy in medicine, the value of OPAT is in doubt because of the lack of published information concerning outcomes and its impact on patient care. In order to examine the quality of such programmes, an outcome-based registry of patients has been developed for OPAT. The core outcomes measures include clinical effectiveness, eradication of bacteria and adverse antibiotic events. The registry may also be adapted for benchmarking for quality assurance, surveying performance of new antimicrobials, cost effectiveness studies and comparisons of different antibiotics and their side effects.

* Corresponding author. Tel: +44-1382-660111; Fax: +44-1382-816178; E-mail: dilip.nathwani{at}tuht.scot.nhs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
P. C. Matthews, C. P. Conlon, A. R. Berendt, J. Kayley, L. Jefferies, B. L. Atkins, and I. Byren
Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years
J. Antimicrob. Chemother., August 1, 2007; 60(2): 356 - 362.
[Abstract] [Full Text] [PDF]

Home page
 Emerg. Med. J.Home page
M Donald, N Marlow, E Swinburn, and M Wu
Emergency department management of home intravenous antibiotic therapy for cellulitis
Emerg. Med. J., October 1, 2005; 22(10): 715 - 717.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
P. Corwin, L. Toop, G. McGeoch, M. Than, S. Wynn-Thomas, J E. Wells, R. Dawson, P. Abernethy, A. Pithie, S. Chambers, et al.
Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital
BMJ, January 15, 2005; 330(7483): 129.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Nathwani, G. D. Barlow, K. Ajdukiewicz, K. Gray, J. Morrison, B. Clift, A. J. France, and P. Davey
Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy
J. Antimicrob. Chemother., February 1, 2003; 51(2): 391 - 396.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.